title: Re: Pasquale Rescigno, David Lorente, Diletta Bianchini, et al. Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer. Eur Urol 2016;70:724-31.
authors.affiliation: Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori IRCCS, Meldola, Italy.
authors.forename: Vincenza
authors.initials: V
authors.lastname: Conteduca
authors.affiliation: Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori IRCCS, Meldola, Italy.
authors.forename: Cristian
authors.initials: C
authors.lastname: Lolli
authors.affiliation: Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori IRCCS, Meldola, Italy. Electronic address: ugo.degiorgi@irst.emr.it.
authors.forename: Ugo
authors.initials: U
authors.lastname: De Giorgi
mesh_terms: D000069501:Abiraterone Acetate; D000736:Androstenes; D006801:Humans; D008297:Male; D017430:Prostate-Specific Antigen; D064129:Prostatic Neoplasms, Castration-Resistant; D043823:Taxoids
chemical_list: D000736:Androstenes; D043823:Taxoids; D017430:Prostate-Specific Antigen; D000069501:Abiraterone Acetate